Cofactor Biosynthetic Pathways in Mycobacterium tuberculosis as Potential Drug Targets

ISSN: 1875-6387 (Online)
ISSN: 1573-398X (Print)

Volume 13, 4 Issues, 2017

Download PDF Flyer

Current Respiratory Medicine Reviews

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Submit Abstracts Online Submit Manuscripts Online

Joseph Varon
The University of Texas Health Science Center
Houston, TX

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Cofactor Biosynthetic Pathways in Mycobacterium tuberculosis as Potential Drug Targets

Current Respiratory Medicine Reviews, 10(2): 97-108.

Author(s): Shilpika Pandey, Sarthak Gaur, Neha Topno, Sidharth Chopra and Arunava Dasgupta.

Affiliation: Division of Microbiology, CSIR-Central Drug Research Institute, B.S. 10/1, Sector 10, Janakipuram Extension, Sitapur Road, Lucknow - 226031, Uttar Pardesh, India.


There are many chemotherapeutic interventions available for tuberculosis (TB) and are in use for more than five decades, but still there is an urgent need for novel drugs against new targets due to emergence of resistant strains. Moreover, the ability of Mycobacterium tuberculosis (Mtb) to survive within granulomas in a non-replicating latent stage prolongs the course of drug dose and hence increases the severity of the disease. The significant rerouting of metabolism is one of the key processes that help mycobacteria adapt to the hostile environment of host granuloma. In this review, we are focusing on some of the cofactor biosynthetic pathways of Mycobacterium tuberculosis and their utilization as drug targets.


FAD, Mtb, NAD, Pantothenate, iron, vitamin.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 10
Issue Number: 2
First Page: 97
Last Page: 108
Page Count: 12
DOI: 10.2174/1573398X10666140822004506
Price: $58
Global Biotechnology Congress 2017Drug Discovery and Therapy World Congress 201713th Asthma & COPD

Related Journals

Webmaster Contact: Copyright © 2017 Bentham Science